Smoking cessation after cancer diagnosis is linked to improved overall survival even for advanced cancers, according to a recent study.

A prespecified analysis of the SURPASS-CVOT trial assessed the efficacy and safety of tirzepatide compared with dulaglutide on kidney outcomes in patients with very high-risk CKD and type 2 diabetes.

Topline data were announced from a phase 3 study evaluating obinutuzumab in patients between 2 and 25 years of age with idiopathic nephrotic syndrome.

Investigators analyzed exfoliated cells in urine test specimens to identify 50 candidate RNAs for prostate cancer detection.

Given the success of atacicept in phase 2 trials, investigators tested the dual inhibitor of BAFF and APRIL in patients with IgA nephropathy in the phase 3 ORIGIN trial.

Longer-term exposure to testosterone therapy was associated with an increased risk for major adverse cardiovascular events among men.

Topline data were announced from a phase 3 trial evaluating obinutuzumab in adults with systemic lupus erythematosus on standard therapy.

Any aspirin use linked to lower hazards of MI, ischemic stroke, with greater benefit in high-frequency use group.

Study reveals 5.05 percent of individuals carry pathogenic/likely pathogenic variants in in large, unselected U.S. population.

Lower risk for MCI and dementia also seen with moderate, high cardiovascular health in those with high polygenic risk score.

Belimumab is linked to a reduced risk for all-cause mortality compared with azathioprine, methotrexate, and mycophenolate among patients with nonrenal SLE.

Akebia Therapeutics has decided not to initiate a clinical trial assessing vadadustat in patients with late-stage CKD not on dialysis.